CRO/Sponsor

DSPMs offer a new skill set to drive data-heavy clinical trials and meet the needs of an evolving landscape.

A look into the work-life benefits that are offered at a large contract research organization.

A look into the work-life benefits that are offered at a small contract research organization.

The need for collaboration between the various disciplines and stakeholders is becoming crucial.

As CRO business and operational models change, so do the opportunities for CRAs.

A look into the country's job market today and what's driving many employees to company hop.

How the Web revolutionizes sharing and learning for clinical trial professionals.

A purely empirical approach to drug development may allow for evaluation of the overt factors that impact the balance of benefit and risk, but it will never uncover all potential scenarios for which companies are now being held accountable.

By defining hurdles to registration, emerging companies benefit from early regulatory guidance.

The public considers clinical research important, but they're not fans of the people behind it.

Can the historical industry and vendor service relationship change to one where both parties benefit?

Outsourcing fundamentals for this pick-and-choose model so that both sponsors and service providers win.

Productive relationships with CROs require a well thought out strategy on the part of sponsors.

Integrating clinical trials and named patient programs to provide global access to drugs before approval.

Norbert Clemens, MD, head of clinical development for CRS Clinical Research Services, explains that EDC is more than just technology; it is indeed the new way of thinking about clinical research.

How leveraging local expertise can make the migration east smoother for companies.

Outsourcing finance and accounting can provide cost savings and improve operations.

A recent survey uncovers key criteria that influence a sponsor's decision when selecting a CRO.

Today's sponsors are waking up to the fact that changes made between phases can positively impact R&D.

Peek into a future where drugs are approved faster and R&D is less costly thanks to technology.

Performance and noncompliance clauses change the partnership between sponsor and vendor.

Readers respond to the NEJM article mentioned in November's From the Editor

Strategies for labs to support global trials and meet the needs of sponsors worldwide.

A look at ECG evaluation for drug-related alterations in repolarization and Torsade de Pointes.

To select the right CRO as an imaging partner, sponsors must first be aware of what to look for.